被忽視的熱帶疾病治療市場規模、佔有率和成長分析：按疾病類型、治療方法、藥物類別、分銷管道、最終用戶和地區分類—2026-2033年行業預測

2024 年全球被忽視的熱帶疾病市場價值為 33 億美元，預計到 2033 年將從 2025 年的 36 億美元成長到 71.7 億美元，預測期（2026-2033 年）的複合年成長率為 9.0%。

被忽視的熱帶疾病治療市場的需求主要源於低收入地區面臨的嚴峻健康挑戰，這導致對有效且擴充性解決方案的持續需求。該領域涵蓋血吸蟲病、淋巴絲蟲病和沙眼等疾病的藥物、診斷和管理系統，這些疾病對生產力、兒童發展和醫療基礎設施造成嚴重影響。合作舉措正從慈善捐贈轉向系統性採購，製造商透過捐贈項目和加強疾病分佈圖繪製來最佳化資源配置。官民合作關係的增加降低了市場准入門檻，並使國家機構能夠開展大規模資金籌措管理（MDA）計畫。此外，診斷技術和地理空間測繪的進步改善了治療資源的分配，而鼓勵本地生產的獎勵和簡化的監管流程則為吸引投資創造了有利環境。

全球被忽視的熱帶疾病治療市場促進因素

全球被忽視的熱帶疾病治療藥物市場正受到公共衛生舉措的推動，這些措施促使各國政府和衛生組織更加重視被忽視的熱帶疾病控制計畫。這些措施的加強正在改善供應鏈管理、協調分銷活動，並擴大對有需要社區的支持。因此，在與製造商和非營利組織夥伴關係的支持下，有效治療方法的研發和採購活動日益活躍，減輕了偏遠地區民眾面臨的後勤挑戰。此外，政府加強制定支持政策並提供可靠的資金支持，這反過來又鼓勵製藥公司擴大產能，促進市場持續成長，並確保民眾能夠持續獲得必要的治療藥物。

全球被忽視的熱帶疾病治療藥物市場面臨的限制因素

由於許多流行地區醫療基礎設施不足，全球被忽視的熱帶疾病治療市場面臨許多限制因素，阻礙了治療藥物的有效提供和持續使用。準確診斷困難、低溫運輸管理難題以及確保持續的後續護理等挑戰限制了患者獲得治療的機會。訓練有素的醫護人員短缺和診所容量不足進一步阻礙了大規模藥物分發舉措和針對性治療工作，導致受影響人群的治療覆蓋率和依從性降低。這些系統性問題給製藥公司和衛生部門都帶來了複雜的挑戰，阻礙了分銷管道的拓展，使創新治療方法的引入變得困難，並最終阻礙了市場成長和切實公共衛生效益的實現。

全球被忽視的熱帶疾病治療市場趨勢

在全球被忽視的熱帶疾病治療市場中，公私合營創新模式的顯著轉變顯而易見。這些策略夥伴關係匯集了產業相關人員、基金會、學術機構和社區組織，旨在加速治療方法的研發和推廣。透過將商業性優勢與公共衛生目標結合，這些合作能夠有效分擔風險、促進技術轉讓，並使供應鏈適應當地需求。注重能力建設、臨床研究網路和基於結果的協議，有助於提高治療的永續可及性，加速創新治療方法的引入，並加強當地醫療衛生體系。因此，對以往服務不足的疾病領域的投資得以促進。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球被忽視的熱帶疾病治療市場規模：按地區和疾病類型分類。

• 登革熱
• 南美錐蟲病
• 利什曼原蟲症
• 淋巴絲蟲病
• 血吸蟲病
• 盤尾絲蟲病
• 沙眼
• 土源性寄生蟲疾病
• 人類非洲錐蟲病
• 其他

全球被忽視的熱帶疾病治療市場規模：依治療類型分類

• 藥物治療
• 疫苗
• 支持性護理

全球被忽視的熱帶疾病治療藥物市場規模：依藥物類別分類

• 抗寄生蟲藥物
• 抗生素
• 抗病毒藥物
• 抗真菌藥物

全球被忽視的熱帶疾病治療市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房
• 政府和非政府組織供應計劃

全球被忽視的熱帶疾病治療市場規模：以最終用戶分類

• 醫院
• 專科診所
• 區域醫療中心
• 研究機構
• 公共衛生組織
• 其他

全球被忽視的熱帶疾病治療市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• GlaxoSmithKline plc
• Pfizer Inc.
• Merck & Co., Inc.
• Johnson & Johnson
• Sanofi SA
• Novartis AG
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• AstraZeneca plc
• Eisai Co., Ltd.
• Takeda Pharmaceutical Company Limited
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Sun Pharmaceutical Industries Limited
• Lupin Limited
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Ltd.

結論與建議

Global Neglected Tropical Disease Treatment Market size was valued at USD 3.3 Billion in 2024 and is poised to grow from USD 3.6 Billion in 2025 to USD 7.17 Billion by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).

The neglected tropical disease treatment market is driven by the significant health challenges faced in low-income regions, creating ongoing demand for effective, scalable interventions. This sector encompasses pharmaceuticals, diagnostics, and delivery systems for diseases like schistosomiasis, lymphatic filariasis, and trachoma, which severely impact productivity, child development, and healthcare infrastructure. Collaborative initiatives have evolved from charitable actions to structured procurement, with manufacturers contributing through donation programs and enhanced disease mapping to optimize resource allocation. Increased financing from public-private partnerships has lowered market entry barriers, enabling extensive mass drug administration (MDA) programs by national entities. Additionally, advancements in diagnostics and geospatial mapping have improved the allocation of treatment resources, while local production incentives and streamlined regulatory processes have fostered a conducive environment for attracting investments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neglected Tropical Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neglected Tropical Disease Treatment Market Segments Analysis

Global neglected tropical disease treatment market is segmented by disease type, treatment type, drug class, distribution channel, end user and region. Based on disease type, the market is segmented into Dengue, Chagas Disease, Leishmaniasis, Lymphatic Filariasis, Schistosomiasis, Onchocerciasis, Trachoma, Soil-Transmitted Helminthiasis, Human African Trypanosomiasis and Others. Based on treatment type, the market is segmented into Drug Therapy, Vaccines and Supportive Therapy. Based on drug class, the market is segmented into Antiparasitic Drugs, Antibacterial Drugs, Antiviral Drugs and Antifungal Drugs. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Government & NGO Supply Programs. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Community Healthcare Centers, Research Institutes, Public Health Organizations and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neglected Tropical Disease Treatment Market

The global market for neglected tropical disease treatments is propelled by heightened public health initiatives that enhance the focus on neglected tropical disease programs by governments and health organizations. This intensification leads to improved supply chain management, coordinated distribution efforts, and expanded outreach to communities in need. As a result, there is an increased drive for the development and procurement of effective treatments, bolstered by partnerships with manufacturers and nonprofit entities that mitigate logistical challenges faced by remote populations. Additionally, stronger government commitment translates into supportive policies and reliable funding, which incentivizes manufacturers to boost production capacity, fostering consistent market growth and ongoing access to essential therapies.

Restraints in the Global Neglected Tropical Disease Treatment Market

The Global Neglected Tropical Disease Treatment market faces significant restraints due to inadequate healthcare infrastructure in many endemic regions, which hampers the effective provision and ongoing utilization of treatments. Challenges such as difficulties in accurate diagnosis, managing cold chain requirements, and ensuring consistent follow-up care limit accessibility. The shortage of trained healthcare professionals and insufficient clinic capacity further obstruct mass drug distribution initiatives and targeted treatment efforts, leading to reduced reach and adherence among affected populations. These systemic issues create complexities for both manufacturers and health authorities, discouraging the expansion of distribution channels, complicating the implementation of innovative therapies, and ultimately hindering market growth and the realization of tangible public health benefits.

Market Trends of the Global Neglected Tropical Disease Treatment Market

The Global Neglected Tropical Disease Treatment market is witnessing a significant trend towards public-private innovation collaborations. These strategic partnerships unite industry stakeholders, foundations, academic institutions, and community organizations to expedite the development and delivery of treatments. By aligning commercial strengths with public health goals, these collaborations effectively share risks and facilitate technology transfer while adapting supply chains to meet local needs. A focus on capacity building, clinical research networks, and outcome-based agreements enhances sustainable access to treatments, encourages the adoption of innovative therapies, and bolsters local health systems, ultimately driving investment in areas of historically underserved diseases.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Neglected Tropical Disease Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Dengue
• Chagas Disease
• Leishmaniasis
• Lymphatic Filariasis
• Schistosomiasis
• Onchocerciasis
• Trachoma
• Soil-Transmitted Helminthiasis
• Human African Trypanosomiasis
• Others

Global Neglected Tropical Disease Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Drug Therapy
• Vaccines
• Supportive Therapy

Global Neglected Tropical Disease Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antiparasitic Drugs
• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

Global Neglected Tropical Disease Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Government & NGO Supply Programs

Global Neglected Tropical Disease Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Community Healthcare Centers
• Research Institutes
• Public Health Organizations
• Others

Global Neglected Tropical Disease Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Drug Class, Distribution Channel, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Drug Class, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Drug Class, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Drug Class, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Drug Class, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations